The preliminary results of the 28-day, 30-patient, randomized, double-blind, placebo-controlled, crossover study showed that P-552-02 was safe and well tolerated, both locally in the oral cavity and systemically. No side effects or other safety issues were reported in the study.
Ross Johnson, Parion’s CEO, said: “Based on these results, we plan to proceed with a Phase I/IIA study designed to test the efficacy of higher concentrations of P-552-02 delivered in a spray formulation and dosing at different intervals, and to pursue other potential indications.”